About Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:FATE
- CUSIP: N/A
- Web: www.fatetherapeutics.com
- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 7.21%
- Quick Ratio: 7.21%
Sales & Book Value:
- Annual Sales: $4.40 million
- Price / Sales: 40.46
- Book Value: $1.10 per share
- Price / Book: 3.88
- Trailing EPS: ($0.94)
- Net Income: $-33,460,000.00
- Net Margins: -935.09%
- Return on Equity: -64.55%
- Return on Assets: -46.97%
- Employees: 66
- Outstanding Shares: 41,690,000
Frequently Asked Questions for Fate Therapeutics (NASDAQ:FATE)
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The company's revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.
Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?
5 equities research analysts have issued 1-year target prices for Fate Therapeutics' shares. Their predictions range from $7.00 to $8.00. On average, they anticipate Fate Therapeutics' stock price to reach $7.20 in the next twelve months. View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. HC Wainwright analysts commented, "Early Encouraging Data With FATE-NK 100 in r/r AML at SITC Significant reductions of leukemic blasts observed in two patients. This morning, Fate reported initial clinical data from the ongoing VOYAGE Phase 1 study, which is investigating FATE-NK100 as a monotherapy for the treatment of r/r acute myelogenous leukemia (AML). After a single dose of FATE-NK100, we note that a subject in the second dose cohort (2×10 7 cells/kg) achieved a morphologic leukemia-free state (mLFS). At day 14, a bone marrow biopsy indicated total clearance of leukemic blasts in the marrow. A second patient from the first dose cohort of VOYAGE (1×10 7 cells/kg) had approximately 50% reduction in leukemic blasts. This patient had a tremendous high disease burden (87% blasts in the marrow). The patient that had the total clearance of leukemic blasts in the marrow had approximately 3×10 4 FATE-NK100 cells per mL in the peripheral blood at day 14 following treatment. In the other patient, after two weeks, approximately 76% of NK cells in the peripheral blood were of FATE-NK100 origin. We view these results as promising and look forward to additional data at higher doses as no dose limiting toxicities (DLTs) were reported so far. The next dose cohort is 1×10 8 cells/kg. In the trial, we note that FATE-NK100 cells persisted in both subjects for at least 14 days with a single dose. We believe this will play an important role for upcoming studies where Fate plans to investigate the combination of FATE-NK100 in advanced solid tumors with monoclonal antibody therapy." (11/10/2017)
- 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (10/17/2017)
- 3. BMO Capital Markets analysts commented, "We are raising our price target to $7 from $4, following 4Q16 earnings that underlined growing interesting in Fate's earlier stage assets, NK100 and iPSC. Our DCF valuation increases as we assign value for these therapies to continue revenue growth beyond ProTmune. We expect ProTmune Phase I interim data in mid-2017 and NK100 to enroll its first AML patient in 2Q17. Fate's hnCD16-iNK could start human trials by early 2018. While we see tremendous potential in the NK100 and iPSC platforms, we wait for clinical validation before including them in our model." (3/17/2017)
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include AVEO Pharmaceuticals (AVEO), Stemline Therapeutics (STML), Calithera Biosciences (CALA), MannKind Corporation (MNKD), NuCana PLC Sponsored ADR (NCNA), Mast Therapeutics (SVRA), Bellicum Pharmaceuticals (BLCM), Biotie Therapies Corp (BITI), BioTime (BTX), Ra Pharmctl (RARX), Geron Corporation (GERN), BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Edge Therapeutics (EDGE), Pieris Pharmaceuticals (PIRS), Arrowhead Pharmaceuticals (ARWR), Circassia Pharmaceuticals PLC (CIR) and Ardelyx (ARDX).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
- J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director (Age 44)
- John D. Mendlein Ph.D., Vice Chairman of the Board (Age 57)
- Jim Beitel, Senior Vice President - Corporate Development
- Daniel D. Shoemaker Ph.D., Chief Scientific Officer (Age 47)
- John Ferraro, Vice President - Clinical Operations
- Wendy Levin, Vice President - Clinical Development
- Walter Grubb, Vice President - Business Development
- Cindy Tahl J.D., General Counsel
- Stewart Abbot Ph.D., Chief Development Officer
Who owns Fate Therapeutics stock?
Fate Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Neuberger Berman Group LLC (0.32%), Victory Capital Management Inc. (0.22%), OxFORD Asset Management LLP (0.19%), Algert Global LLC (0.17%), Russell Investments Group Ltd. (0.14%) and Hochman Cole Investment Advisors Inc. (0.10%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.
Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?
Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC and OxFORD Asset Management LLP. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.
Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?
Fate Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Neuberger Berman Group LLC, Russell Investments Group Ltd. and Hochman Cole Investment Advisors Inc.. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.
How do I buy Fate Therapeutics stock?
Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of Fate Therapeutics stock can currently be purchased for approximately $4.27.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $183 million and generates $4.40 million in revenue each year. The biopharmaceutical company earns $-33,460,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Fate Therapeutics employs 66 workers across the globe.
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Fate Therapeutics (NASDAQ:FATE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$7.20 (68.62% upside)|
Consensus Price Target History for Fate Therapeutics (NASDAQ:FATE)
Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/10/2017||HC Wainwright||Reiterated Rating||Buy||$7.00||N/A|
|11/2/2017||BMO Capital Markets||Reiterated Rating||Buy||$7.00||N/A|
|9/8/2017||Leerink Swann||Reiterated Rating||Outperform -> Outperform||$7.00||Medium|
|3/18/2017||Roth Capital||Set Price Target||Buy||$8.00||Low|
|5/10/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
Earnings History and Estimates Chart for Fate Therapeutics (NASDAQ:FATE)
Earnings History by Quarter for Fate Therapeutics (NASDAQ FATE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/1/2017||Q3 2017||($0.25)||($0.26)||$0.95 million||$1.03 million||View||N/A|
|8/14/2017||Q2 2017||($0.24)||($0.23)||$1.02 million||$1.03 million||View||N/A|
|5/15/2017||Q1 2017||($0.21)||($0.24)||$1.04 million||$1.03 million||View||N/A|
|3/16/2017||Q4 2016||($0.28)||($0.21)||$1.06 million||$1.03 million||View||N/A|
|11/7/2016||Q316||($0.29)||($0.27)||$1.05 million||$1.03 million||View||Listen|
|8/8/2016||Q216||($0.32)||($0.29)||$1.02 million||$1.03 million||View||N/A|
|5/9/2016||Q116||($0.25)||($0.29)||$0.84 million||$1.32 million||View||N/A|
|3/3/2016||Q415||($0.27)||($0.26)||$0.58 million||$1.08 million||View||N/A|
|11/3/2015||Q315||($0.32)||($0.24)||$0.46 million||$1.03 million||View||N/A|
|8/5/2015||Q215||($0.39)||($0.33)||$0.31 million||$0.33 million||View||N/A|
Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
2017 EPS Consensus Estimate: ($0.98)
2018 EPS Consensus Estimate: ($1.02)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fate Therapeutics (NASDAQ FATE)
Insider Ownership Percentage: 10.88%
Institutional Ownership Percentage: 63.08%
Insider Trades by Quarter for Fate Therapeutics (NASDAQ FATE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/16/2017||Cindy Tahl||General Counsel||Sell||8,091||$3.85||$31,150.35|| |
|10/16/2017||Daniel D Shoemaker||Insider||Sell||13,225||$3.87||$51,180.75|| |
|11/23/2016||Chris Storgard||Insider||Buy||37,593||$2.66||$99,997.38|| |
|11/23/2016||William H Rastetter||Director||Buy||375,939||$2.66||$999,997.74|| |
|6/12/2014||Peter D Flynn||Insider||Sell||6,488||$7.00||$45,416.00|| |
|6/10/2014||Peter D Flynn||Insider||Sell||3,305||$7.00||$23,135.00|| |
|5/1/2014||Peter D Flynn||Insider||Sell||9,793||$7.07||$69,236.51|| |
|4/4/2014||Peter D Flynn||Insider||Sell||5,889||$8.00||$47,112.00|| |
|4/2/2014||Christian Weyer||Insider||Sell||10,000||$9.02||$90,200.00|| |
|4/1/2014||J Scott Wolchko||Insider||Sell||20,000||$9.64||$192,800.00|| |
|3/31/2014||Daniel D Shoemaker||CTO||Sell||8,653||$9.86||$85,318.58|| |
|10/4/2013||John Mendlein||Director||Buy||16,667||$6.00||$100,002.00|| |
|10/4/2013||Venture Fund Vi Lp Arch||Major Shareholder||Buy||833,333||$6.00||$4,999,998.00|| |
Latest Headlines for Fate Therapeutics (NASDAQ FATE)
| Analysts Expect Fate Therapeutics, Inc. (FATE) Will Post Quarterly Sales of $1.02 Million|
www.americanbankingnews.com - November 20 at 9:04 AM
|ETFs with exposure to Fate Therapeutics, Inc. : November 17, 2017|
finance.yahoo.com - November 17 at 12:12 PM
|Boston Children's reverses type 1 diabetes in mice|
finance.yahoo.com - November 16 at 2:10 PM
|Fate Therapeutics, Inc. (FATE) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - November 15 at 1:46 AM
|Fate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML at SITC|
www.streetinsider.com - November 10 at 7:48 PM
|BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100|
www.reuters.com - November 10 at 7:48 PM
|HC Wainwright Reaffirms "Buy" Rating for Fate Therapeutics, Inc. (FATE)|
www.americanbankingnews.com - November 10 at 2:48 PM
|Fate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML ... - StreetInsider.com|
www.streetinsider.com - November 10 at 2:44 PM
|Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting|
finance.yahoo.com - November 10 at 2:44 PM
|ETFs with exposure to Fate Therapeutics, Inc. : November 6, 2017|
finance.yahoo.com - November 6 at 8:17 PM
|Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017|
finance.yahoo.com - November 3 at 12:29 PM
|Fate Therapeutics' (FATE) CEO Scott Wolchko on Q3 2017 Results ... - Seeking Alpha|
seekingalpha.com - November 2 at 7:49 PM
|Fate Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - November 2 at 7:49 PM
|Fate Therapeutics, Inc. (FATE) Issues Earnings Results|
www.americanbankingnews.com - November 2 at 3:06 PM
|Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting|
finance.yahoo.com - November 1 at 7:41 PM
|Fate Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - November 1 at 7:41 PM
|Fate Therapeutics Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 1 at 7:41 PM
|Fate Therapeutics reports 3Q loss|
finance.yahoo.com - November 1 at 7:41 PM
|Fate Therapeutics, Inc. (FATE) Expected to Post Quarterly Sales of $1.02 Million|
www.americanbankingnews.com - October 31 at 9:00 AM
|Fate Therapeutics, Inc. (FATE) to Release Earnings on Monday|
www.americanbankingnews.com - October 30 at 9:15 AM
|Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results|
finance.yahoo.com - October 25 at 9:00 PM
|Fate Therapeutics (FATE) & Its Peers Critical Review|
www.americanbankingnews.com - October 22 at 2:28 AM
|Fate Therapeutics, Inc. (FATE) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 21 at 3:04 AM
|Form 4 FATE THERAPEUTICS INC For: Oct 13 Filed by: TAHL CINDY - StreetInsider.com|
www.streetinsider.com - October 18 at 7:57 PM
|Zacks Investment Research Downgrades Fate Therapeutics, Inc. (FATE) to Hold|
www.americanbankingnews.com - October 17 at 10:58 PM
|Cindy Tahl Sells 8,091 Shares of Fate Therapeutics, Inc. (FATE) Stock|
www.americanbankingnews.com - October 17 at 8:18 PM
|Fate Therapeutics, Inc. (FATE) Insider Daniel D. Shoemaker Sells 13,225 Shares|
www.americanbankingnews.com - October 17 at 8:18 PM
|ETFs with exposure to Fate Therapeutics, Inc. : October 16, 2017|
finance.yahoo.com - October 16 at 6:56 PM
|4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate ... - Benzinga|
www.benzinga.com - October 13 at 12:23 AM
|4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate|
finance.yahoo.com - October 12 at 7:22 PM
|$1.01 Million in Sales Expected for Fate Therapeutics, Inc. (FATE) This Quarter|
www.americanbankingnews.com - October 12 at 10:54 AM
|Fate Therapeutics, Inc. (FATE) Coverage Initiated by Analysts at HC Wainwright|
www.americanbankingnews.com - October 12 at 8:02 AM
|ETFs with exposure to Fate Therapeutics, Inc. : October 5, 2017|
finance.yahoo.com - October 5 at 5:41 PM
|Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017|
finance.yahoo.com - October 4 at 9:49 AM
|Fate Therapeutics, Inc. (FATE) Short Interest Update|
www.americanbankingnews.com - September 30 at 3:26 AM
|Fate Therapeutics (FATE) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow|
seekingalpha.com - September 28 at 1:11 PM
|Fate Therapeutics Inc (FATE) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - September 26 at 2:44 AM
|What 'Fate' Lies Ahead For This ~$4 Biotech Busted IPO? - Seeking Alpha|
seekingalpha.com - September 21 at 6:43 PM
|-$0.25 EPS Expected for Fate Therapeutics, Inc. (FATE) This Quarter|
www.americanbankingnews.com - September 21 at 12:24 PM
|Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% - Seeking Alpha|
seekingalpha.com - September 19 at 11:38 PM
|Fate Therapeutics (FATE) Initiates Phase 2 PROTECT Study of ProTmune for Prevention of GvHD|
www.streetinsider.com - September 19 at 6:34 PM
|BRIEF-Fate Therapeutics initiates Phase 2 PROTECT study of ProTmune|
www.reuters.com - September 19 at 6:34 PM
|Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease - Nasdaq|
www.nasdaq.com - September 18 at 11:22 PM
|Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease|
finance.yahoo.com - September 18 at 6:22 PM
|Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development - GlobeNewswire (press release)|
globenewswire.com - September 14 at 7:15 PM
|Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development|
finance.yahoo.com - September 14 at 7:15 PM
|Keryx Biopharma (KERX) Names Michael Rogers as Chairman Following Resignation of John Butler|
www.streetinsider.com - September 13 at 7:54 PM
|Fate Therapeutics, Inc. (FATE) Receives Outperform Rating from Leerink Swann|
www.americanbankingnews.com - September 8 at 8:42 PM
|$1.02 Million in Sales Expected for Fate Therapeutics, Inc. (FATE) This Quarter|
www.americanbankingnews.com - September 4 at 1:48 AM
|-$0.24 Earnings Per Share Expected for Fate Therapeutics, Inc. (FATE) This Quarter|
www.americanbankingnews.com - September 2 at 8:26 PM
Fate Therapeutics (NASDAQ FATE) Chart for Wednesday, November, 22, 2017